Sarepta Therapeutics Inc (SRPT)
Solvency ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 2.59 | 3.80 | 8.13 | 3.39 | 3.92 |
Sarepta Therapeutics Inc has consistently maintained a strong solvency position as indicated by its debt-related ratios. The Debt-to-assets ratio has remained at 0.00 for the last five years, suggesting that the company has no debt relative to its total assets during this period. Similarly, the Debt-to-capital ratio and Debt-to-equity ratio have also remained at 0.00 throughout the period, indicating that Sarepta has not relied on debt to finance its operations.
The Financial leverage ratio, which measures the extent to which the company is utilizing debt in its capital structure, shows some fluctuations. It was 3.92 in 2020, decreased to 3.39 in 2021, spiked to 8.13 in 2022, dropped to 3.80 in 2023, and further decreased to 2.59 in 2024. Despite the fluctuations, the Financial leverage ratio generally remains moderate, indicating that Sarepta has a balanced mix of debt and equity in its capital structure. Overall, the company's solvency ratios reflect a healthy financial position with minimal reliance on debt for its operations.
Coverage ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Interest coverage | 15.18 | -22.63 | -11.96 | -5.60 | -8.23 |
Based on the interest coverage ratios for Sarepta Therapeutics Inc for the years presented, it is evident that the company has been experiencing challenges in meeting its interest payment obligations from its operating income. The negative values for the interest coverage ratios indicate that the company's operating income is insufficient to cover its interest expenses during these periods.
Specifically, the interest coverage ratio was -8.23 as of December 31, 2020, -5.60 as of December 31, 2021, -11.96 as of December 31, 2022, and -22.63 as of December 31, 2023, reflecting a worsening financial position in terms of ability to cover interest payments.
However, there was a significant improvement in the interest coverage ratio to 15.18 as of December 31, 2024. This positive ratio indicates that Sarepta Therapeutics Inc's operating income was sufficient to cover its interest expenses and even had excess coverage during this specific period.
Overall, the trend in the interest coverage ratios reveals periods of financial distress followed by a notable recovery in the company's ability to cover its interest obligations. Further analysis and monitoring of the company's financial performance will be essential to assess the sustainability of this improvement.